• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg342Leu (c.1025G>T); ClinVar=VCV001055894; Zygosity=Unspecified (PubMed=11507071).
  

PubMed=11507071
Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., Triche T.J., Reynolds C.P.
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Cancer Res. 61:6185-6193(2001)

PubMed=18724359; DOI=10.1038/nature07261; PMCID=PMC2672043
Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M.
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature 455:930-935(2008)

PubMed=20922763; DOI=10.1002/pbc.22801; PMCID=PMC3005554
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=28340497; DOI=10.1002/ijc.30706
Lopez-Barcons L., Maurer B.J., Kang M.H., Reynolds C.P.
P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
Int. J. Cancer 141:405-413(2017)